한글목차

2024년 ACLF(만성 간부전 급성 악화)의 발병 횟수는 7만 1,713건으로, 2028년까지 7만 3,804건으로 증가할 것으로 예측됩니다.

현재 ACLF에 대해 승인된 치료법은 없습니다.

현재 ACLF의 후기 개발 파이프라인(3단계, 등록 전)에는 후보 약물이 없습니다.

지난 10년간 ACLF를 대상으로 71건의 임상시험이 시작되었습니다. 2019년·2023년에 시작된 시험이 가장 많았고, 각각 11건이었습니다.

지난 10년간 ACLF 관련 거래는 주로 북미, 유럽, 아시아태평양에서 이루어졌습니다. 북미에서는 거래의 66.7%가 합병이고 33.3%가 인수였습니다.

본 보고서에서는 세계의 ACLF(만성 간부전의 급성 악화) 시장에 대해 조사 분석하여 질병 상황, 시상한 약품 및 파이프라인 의약품의 평가, 현재와 미래 경쟁 구도 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질병의 개요
• 역학의 개요
• 치료 개요

제4장 상시이 끝난 약품의 평가

• 주요 상시 끝난 약품
• 개요 : 작용기전별
• 개요 : 분자 유형별
• 제품 프로파일, 매출 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지의 시간

제6장 파이프라인 의약품 평가

• 중기-후기의 파이프라인 의약품
• 개요 : 개발 단계별
• 개요 : 작용기전별
• 개요 : 분자 유형별
• 약품 고유의 위상 전환 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증 고유의 PTSR과 LoA

제7장 임상시험 평가

• 과거의 개요
• 개요 : 페이즈별
• 개요 : 스테이터스별
• 개요: 페이즈별(진행중/계획이 끝난 시험)
• 가상 컴포넌트에 의한 시험
• 시험의 개요 : 지역별
• 단일국/다국간 시험:지역별
• 스폰서 상위 20개사와 내역: 페이즈별
• 스폰서 상위 20사와 내역 : 스테이터스별
• 개요 : 엔드포인트 스테이터스별
• 개요: 인종/민족별
• 등록 데이터
• 시험 시설의 상위 20개국
• 세계의 주요 20개 시설
• 실현 가능성 분석 - 지리적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴:지역별
• 최근의 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 미래 시장 카탈리스트

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Acute-on-Chronic Liver Failure therapeutics.

GlobalData epidemiologists estimated that there are 71,713 diagnosed incident cases of acute-on-chronic liver failure (ACLF) in 2024, which is expected to increase to 73,804 diagnosed incident cases by 2028.

Currently there are no approved therapies for ACLF.

There are currently no candidates in the late-stage development pipeline (Phase III and pre-registration) for ACLF.

Over the past decade, 71 trials have been initiated for ACLF. The years 2019 and 2023 saw the most trials initiated, with 11 trials each.

Over the decades, ACLF-related deals have primarily taken place in North America, Europe, and Asia-Pacific. In North America, 66.7% of deals were mergers while 33.3% were acquisitions.

Scope

GlobalData's Acute-on-Chronic Liver Failure: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Acute-on-Chronic Liver Failure market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Acute-on-Chronic Liver Failure market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer